Utilization of an amorphous form of a water-soluble GPIIb/IIIa antagonist for controlled release from biodegradable microspheres

Pharmaceutical Research

Volumn 14, Issue 9, 1997, Pages 1146-1150

  Takada, Shigeyuki ^a   Kurokawa, Tomofumi ^a   Miyazaki, Keiko ^a   Iwasa, Susuniu ^a   Ogawa, Yasuaki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Amorphous; Controlled release; GPIIb IIIa antagonist; Microspheres; PLGA

Indexed keywords

4 (4 AMIDINOBENZOYLGLYCYL) 3 METHOXYCARBONYLMETHYL 2 OXO 1 PIPERAZINEACETIC ACID; ARGININE; FIBRINOGEN RECEPTOR ANTAGONIST; MICROSPHERE; POLYGLACTIN; UNCLASSIFIED DRUG; WATER OIL CREAM;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CRYSTAL STRUCTURE; DISPERSION; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EVAPORATION; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VISCOSITY;

ANIMALS; ARGININE; BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; FIBRINOLYTIC AGENTS; GUANIDINES; LACTIC ACID; MALE; MICROSPHERES; POLYGLYCOLIC ACID; POLYMERS; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030763788     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012190304074     Document Type: Article

References (21)

1. L. M. Sanders, J. S. Kent, G. I. McRae, B. H. Vickery, T. R. Tice, and D. H. Lewis. J. Pharm. Sci. 73:1294-1297 (1984).
2. T. W. Redding, A. V. Schally, T. R. Tice, and W. E. Meyers. Proc. Natl. Acad. Sci. USA 81:5845-5848 (1984).
3. S. Takada, Y. Uda, H. Toguchi, and Y. Ogawa. PDA J. Pharm. Sci. Technol. 49:180-184 (1995).
4. C. Thomasin, P. Johansen, R. Alder, R. Bemsel, G. Hottinger, H. Altorfer, A. D. Wright, G. Wehrli, H. P. Merkel, and B. Gander. Eur. J. Pharm. Biopharm. 42:16-24 (1996).
5. Y. Ogawa, M. Yamamoto, S. Takada, H. Okada, and T. Shimamoto. Chem. Pharm. Bull. 36:1502-1507 (1988).
6. H. Okada, T. Heya, Y. Ogawa, and T. Shimamoto. J. Pharmacol. Exp. Ther. 244:744-750 (1988).
7. T. Heya, H. Okada, Y. Tanigawara, Y. Ogawa, and H. Toguchi. Int. J. Pharm. 69:69-75 (1991).
8. S. Takada, Y. Uda, H. Toguchi, and Y. Ogawa. J. Controlled Release 32:79-85 (1994).
9. The United States Pharmacopoeia, 23rd revision, Supplement 2, Rockville, USA, 1995, pp. 2697-2699.
10. H. Okada, M. Yamamoto, T. Heya, Y. Inoue, S. Kamei, Y. Ogawa, and H. Toguchi. J. Controlled Release 28:121-129 (1994).
11. J. W. Fong, J. P. Nazareno, J. E. Pearson, and H. V. Maulding. J. Controlled Release 3:119-130 (1986).
12. R. Bodmeier, and J. W. McGinity. Pharm. Res. 4:465-471 (1987).
13. R. Jalil, and J. R. Nixon. J. Microencapsulation 7:297-325 (1990).
14. M. Kawamura, Y. Imura, N. Moriya, S. Kita, H. Fukushi, H. Sugihara, K. Nishikawa, and Z. Terashita. J. Pharmacol. Exp. Ther. 277:502-510 (1996).
15. K. Peerlinck, I. De Lepeleire, M. Goldberg, D. Farrell, J. Barrett, E. Hand, D. Panebianco, H. Deckmyn, J. Vermylen, and J. Arnout. Circulation 88:1512-1517 (1993).
16. The EPIC Investigators. N. Engl. J. Med. 330:956-961 (1994).
17. S. Takada, T. Kurokawa, K. Miyazaki, S. Iwasa, and Y. Ogawa. Int. J. Pharm. 146:147-157 (1997).
18. G. Spenlehauer, M. Veillard, and J.-P. Benoit. J. Pharm. Sci. 75:750-755 (1986).
19. G. Spenlehauer, M. Vert, J.-P. Benoit, F. Chabot, and M. Veillard. J. Controlled Release 7:217-229 (1988).
20. B. C. Hancock, and G. Zografi. J. Pharm. Sci. 86:1-12 (1997).
21. T. Yoshioka, H. Okada, and Y. Ogawa. US Patent 5271945 (1993).